Thought of as the premier conference in the immunoglobulin and biologics space, the bustling Immunoglobulin National Society (IgNS) 12th national conference took place at the Sheraton Denver Downtown from Oct. 5 to 8, 2023.
The four-day meeting welcomed more than 1,200 attendees who had access to more than 50 clinical and business sessions. Educational programs, keynote speakers, exhibits, and networking were geared toward nurses, pharmacists, and physicians who are on the front lines of treating myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, common variable immunodeficiency, primary immune thrombocytopenia, immunologic recurrent pregnancy loss, dermatomyositis, polymyositis, and juvenile dermatomyositis, plus other conditions.
Click above for our post-conference wrap-up report.
Serum Metabolomics of Treatment Response in Myasthenia Gravis
Source : https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0287654
Objective High-dose prednisone use, lasting several months or longer, is the primary initial therapy for myasthenia gravis (MG). Upwards of a third of patients do not respond to treatment. Currently...
A now-defined metabolomic and lipidomic profile can undergo validation as a treatment predictive marker for MG patients undergoing corticosteroid therapy. Metabolomic profiles of outcome measures had limited overlap consistent with their assessing distinct aspects of treatment response and supporting unique biological underpinning for each...
Myasthenic Crisis in Thymoma-Associated Myasthenia Gravis: a Multicenter Retrospective Cohort Study
Source : https://pubmed.ncbi.nlm.nih.gov/37783628/
Thymoma-associated myasthenia gravis (TMG) had more severe symptoms and worse prognoses in comparison to non-thymoma-associated MG. Thymoma recurrence was frequently associated with transient worsening of MG and even acute respiratory...
Within the TMG group, the hospital stay was significantly longer in patients with unresected thymoma compared to that in postoperative myasthenic crisis (POMC) (47.68±24.9 [6-111] vs. 34.21±18.87 days [12-82]; P = 0.0257). Early identification of the MG categories may provide some hints in tailoring therapeutic strategies to improve the...
Altered Gut Microbiota and Metabolites in Untreated Myasthenia Gravis Patients
Source : https://pubmed.ncbi.nlm.nih.gov/37789892
Our findings suggest that dysbiosis already exists in newly diagnosed and untreated MG patients, implying that dysbiosis within the gut microbiota may be an initiating factor contributing to MG pathogenesis....
Our findings suggest that dysbiosis already exists in newly diagnosed and untreated MG patients, implying that dysbiosis within the gut microbiota may be an initiating factor contributing to MG pathogenesis. Furthermore, F. prausnitzii may hold promise as a probiotic for treating MG.
Comparison Between Sugammadex and Neostigmine After Video-Assisted Thoracoscopic Surgery-Thymectomy in Patients with Myasthenia Gravis: a Single-Center Retrospective Exploratory Analysis
Source : https://pubmed.ncbi.nlm.nih.gov/37763148/
This single-center retrospective exploratory analysis evaluated the effects of sugammadex compared with neostigmine on postoperative recovery in patients with myasthenia gravis (MG) who underwent video-assisted thoracoscopic surgery (VATS)-thymectomy. This retrospective...
Patients with MG following VATS-thymectomy who received sugammadex showed a significantly shorter postoperative hospital stay than those who received neostigmine.
